Structural characterization and in vivo evaluation of β-Hairpin peptidomimetics as specific CXCR4 imaging agents

Wojciech G Lesniak1, Emilia Sikorska, Hassan Shallal

  • 1Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University , Baltimore, Maryland 21287, United States.

Molecular Pharmaceutics
|January 16, 2015
PubMed

Insights

The POL3026 peptidomimetic template shows promise for developing CXCR4-targeting imaging agents. Despite reduced affinity, its conjugates demonstrated significant tumor uptake and specificity in vivo.

Area of Science:

  • Molecular Biology
  • Radiochemistry
  • Medical Imaging

Background:

  • The CXCR4 chemokine receptor is crucial in biological processes and disease pathophysiology.
  • CXCR4 is a significant target for developing novel imaging and therapeutic agents.
  • Peptidomimetics offer a versatile platform for drug development.

Purpose of the Study:

  • To evaluate the POL3026 peptidomimetic template for creating CXCR4-targeting imaging agents.
  • To analyze the structural and conformational properties of POL3026 and its conjugates.
  • To assess the in vivo efficacy and specificity of radiolabeled POL3026 conjugates.

Main Methods:

  • Structural and conformational analyses using circular dichroism, 2D NMR, and molecular dynamics.
  • In vitro affinity assays and molecular modeling to verify in silico observations.
  • In vivo SPECT/CT imaging and biodistribution studies of [(111)In]-labeled conjugates in U87 tumor models.

Main Results:

  • POL3026 and its DOTA/PEG12-DOTA conjugates showed similar interactions with membrane mimics.
  • The ε-NH2 group of lysine(7) was identified as critical for high CXCR4 affinity.
  • Radiolabeled conjugates exhibited significant tumor uptake in CXCR4-expressing tumors, blocked by unlabeled POL3026, confirming in vivo specificity.

Conclusions:

  • The POL3026 template is a promising foundation for developing effective CXCR4-targeting imaging agents.
  • Conjugation of DOTA or PEG12-DOTA to POL3026 impacts affinity but not in vivo tumor targeting efficacy.
  • The study validates the potential of POL3026-based agents for molecular imaging of CXCR4-expressing diseases.

Related Concept Videos